Braidwell’s Trevi Therapeutics TRVI Stock Holding History

Braidwell’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-72,083	Closed	-$453K	–	63
2025 Q1	$453K	Buy	+72,083	New	+$344K	0.02%	64

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Braidwell's TRVI Position: Q2 2025 in Review

Braidwell sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 72,083 shares — an estimated $453K sold.

Braidwell first reported a position in TRVI in Q1 2025 and held it in 1 quarter. The position peaked at $453K in Q1 2025. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

Braidwell reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
Braidwell sold 72,083 Trevi Therapeutics shares in Q2 2025, an estimated $453K.
Braidwell first reported a position in Trevi Therapeutics in Q1 2025 and held it in 1 quarter.
Braidwell's Trevi Therapeutics position peaked at $453K in Q1 2025.
153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.